Long-Acting Injectable Antipsychotic Medications: Recent Findings
Categories:
Department of Psychiatry,
Department of Psychiatry,
Best Practices in Schizophrenia Treatment (BeST) Center,
Integrated Primary and Mental Health Care,
Integrated Care @ NEOMED (IC@N) Project ECHO,
Department of Psychiatry,
Best Practices in Schizophrenia Treatment (BeST) Center,
Integrated Primary and Mental Health Care,
Department of Psychiatry,
Project ECHO | Tags:
access,
adherence,
anosognosia,
antipsychotic medications,
antipsychotics,
bipolar disorder,
cognitive functioning,
cognitive issues,
cohort studies,
criminal justice system encounters,
data analysis,
delusions,
depression,
descriptive analysis,
dopamine,
dopamine antagonists,
Doug,
Doug Smith,
drug delivery,
drug prescription,
DUP,
duration of untreated psychosis,
early treatment,
effectiveness,
efficacy,
ethical considerations,
executive functioning,
family,
family relationships,
first episode psychosis,
follow-up,
hallucinations,
hospitalization,
incarceration rates,
injectables,
LAI,
LAI treatment,
long-acting injectables,
major depression,
medications,
mortality rates,
natural-cause mortality,
neuroleptics,
OAPs,
oral antipsychotics,
overdose,
poor adherence,
pre-post studies,
primary,
primary psychosis,
psychosis,
psychotropics,
randomized control trials,
recidivism rates,
reduce relapse,
relapse,
retrospective analysis,
reward pathways,
risk of suicide,
risk-reduction,
safety,
schizoaffective,
schizoaffective disorder,
schizophrenia,
secondary,
secondary psychosis,
serious mental illness,
SMI,
Smith,
suicide attempts,
suicide mortality
Findings on long-acting injectable antipsychotic medications are discussed by Dr. Doug Smith.